We are live on ! Find out more
IPHA

Innate Pharma
IPHA

13 hedge funds and large institutions have $2.58M invested in Innate Pharma in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 13 → 13 (0)

0% more ownership

Funds ownership: 1.19% → 1.2% (+0%)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

19% less capital invested

Capital invested by funds: $3.2M → $2.58M (-$623K)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
13
Holders Change
–
Holders Change %
0%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Optiver Holding
Optiver Holding
Netherlands
+$416K
2
UBS Group
UBS Group
Switzerland
+$8.6K
3
TRCT
Tower Research Capital (TRC)
New York
+$7.57K
4
CS
Credit Suisse
Switzerland
+$5.76K
5
Morgan Stanley
Morgan Stanley
New York
+$4.78K

Top Sellers

Rank Fund Capital Flow
1
AA
ALPS Advisors
Colorado
-$282K
2
Jane Street
Jane Street
New York
-$127K
3
Two Sigma Investments
Two Sigma Investments
New York
-$31.4K
4
Millennium Management
Millennium Management
New York
-$24K
5
BlackRock
BlackRock
New York
-$20.8K

IPHA Hedge Fund Activity: Q2 2022 in Review

13 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q2 2022, worth a combined $2.58M — down 19% from $3.2M a quarter earlier.

Fund positioning in IPHA was balanced in Q2 2022: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 4 trimmed.

The largest buyer was Optiver Holding, adding an estimated $416K. The largest seller was ALPS Advisors, exiting entirely with an estimated $282K sold.

  • 13 institutional investors held Innate Pharma (IPHA) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $2.58M of Innate Pharma stock for Q2 2022, down 19% quarter-over-quarter.
  • 3 funds opened new Innate Pharma positions in Q2 2022 and 3 closed out, a net change of 0 holders.
  • The largest Innate Pharma buyer in Q2 2022 was Optiver Holding, an estimated $416K added.
  • The largest Innate Pharma seller in Q2 2022 was ALPS Advisors, an estimated $282K sold.

Based on aggregated 13F filings for Q2 2022.